Synthetic Biologics Inc (SYN) was Reiterated by FBR Capital to “Outperform” while Lowering the Price Target of the company shares to $ 9 from a previous price target of $10 . FBR Capital advised their investors in a research report released on May 6, 2016.
Many Wall Street Analysts have commented on Synthetic Biologics Inc. FBR Capital Initiated Synthetic Biologics Inc on Feb 26, 2016 to “Outperform”, Price Target of the shares are set at $10.
Synthetic Biologics Inc closed down -0.18 points or -8.26% at $2 with 10,22,923 shares getting traded on Wednesday. Post opening the session at $2.13, the shares hit an intraday low of $1.92 and an intraday high of $2.2 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Synthetic Biologics Inc. is a clinical-stage biotechnology company. The Company is developing pathogen-specific therapies for serious infections and diseases with a focus on protecting the microbiome. It is developing an oral biologic to protect the gut microbiome (gastrointestinal (GI) microflora) from intravenous (IV) antibiotics for the prevention of C. difficile infection an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C) and a monoclonal antibody combination for the treatment of Pertussis. In addition the Company is developing a Phase II oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.